Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2026-02-26 00:00:00 ET · period of report 2026-02-24 · accession 0000875320-26-000106 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-26 | 2026-02-25 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | S - Sale | $486.35 | -668 | 18.4K | -3% | -$324.9K | |
| 2026-02-26 | 2026-02-24 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | F - Tax | $485.11 | -1,627 | 19.1K | -8% | -$789.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-25 | S | D | 668 | $486.35 | 18,432 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-24 | F | D | 1,627 | $485.11 | 19,100 | D | — | — |